Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori -resistant strains.

Abstract

Bismuth quadruple therapy (BQT) is the recommended rescue therapy for Helicobacter pylori (H.pylori) infection. This study aimed to assess the efficacy and safety of a 10-day BQT regimen in patients who failed previous therapies and were infected with multiresistant H.pylori strains MATERIALS AND METHODS: Helicobacter pylori-infected patients underwent endoscopy, culture, and susceptibility test for clarithromycin, metronidazole, and levofloxacin. Treatment with three-in-one capsule (Pylera®) four times daily and esomeprazole 20mg twice daily for 10days was administered. Treatment-emergent adverse events (TEAEs) were registered. A total of 116 patients with persistent H.pylori infection following at least one eradication therapy attempt were treated. Overall, resistance toward clarithromycin was detected in 80% of strains, toward metronidazole in 70%, and levofloxacin in 47.5%, with dual or triple resistance in 72.5% of cases. An eradication rate of 81.0% (95% CI: 73.0-87.1) and 87.0% (95% CI: 79.4-92.1) at ITT and PP analyses, respectively, was achieved. The cure rate remained high until it was used as fourth-line regimen, while it dropped to low values (<67%) in those patients with more than 4 therapy failures. A total of 65.7% (95% CI: 56.4-74.0) patients complained of TEAEs. Our data found that bismuth-based quadruple regimen is effective as rescue therapy for curing patients infected with multiresistant H.pylori strains.